Phytic acid as a potential treatment for Alzheimer's pathology: Evidence from animal and in vitro models

Journal of Alzheimer's Disease

Volumn 23, Issue 1, 2011, Pages 21-35

  Anekonda, Thimmappa S ^a,b   Wadsworth, Teri L ^a,b   Sabin, Robert ^c   Frahler, Kate ^a   Harris, Christopher ^b   Petriko, Babett ^a   Ralle, Martina ^b   Woltjer, Randy ^a   Quinn, Joseph F ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Superfox Therapeutics Inc   (United States)

Author keywords

Amyloid ; amyloid protein precursor; antioxidant; autophagy; beclin 1; phosphorylated AMP activated protein kinase; sirtuin 1

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN C; BECLIN 1; CALCIUM; CERULOPLASMIN; COPPER; CYTOCHROME C OXIDASE; DRINKING WATER; HYDROGEN PEROXIDE; IRON; PHYTIC ACID; SIRTUIN 1; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CALCIUM CELL LEVEL; CELL MIGRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; LIPID PEROXIDATION; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 78651356190     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101287     Document Type: Article

References (91)

1. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20, 154-159.
2. Hardy J (2006) Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 9, 151-153.
3. Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52, 3-13.
4. Selkoe DJ (2000) The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol Clin 18, 903-922.
5. Selkoe DJ (2001) Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 98, 11039-11041.
6. SelkoeDJ(2004)Alzheimer disease: mechanisticunderstand-ing predicts novel therapies. Ann Intern Med 140, 627-638.
7. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555.
8. Bonda DJ, Lee HP, Lee HG, Friedlich AL, Perry G, Zhu X, SmithMA(2010) Novel therapeutics for Alzheimer's disease: an update. Curr Opin Drug Discov Devel 13, 235-246.
9. Citron M (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9, 387-398.
10. Bush AI (2008) Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 15, 223-240.
11. Graf E, Eaton JW (1990) Antioxidant functions of phytic acid. Free Radic Biol Med 8, 61-69.
12. Bozsik A, Kokeny S, Olah E (2007) Molecular mechanisms for the antitumor activity of inositol hexakisphosphate (IP6). Cancer Genomics Proteomics 4, 43-51.
13. 2+ channel activity by stimulation of adenylyl cyclase. FASEB J 15, 1753-1763.
14. Norris FA, Ungewickell E, Majerus PW (1995) Inositol hexakisphosphate binds to clathrin assembly protein 3 (AP-3/AP180) and inhibits clathrin cage assembly in vitro. J Biol Chem 270, 214-217.
15. Ye W, Lafer EM (1995) Clathrin binding and assembly activities of expressed domains of the synapse-specific clathrin assembly protein AP-3. J Biol Chem 270, 10933-10939.
16. Wu F, Matsuoka Y, Mattson MP, Yao PJ (2009) The clathrin assembly protein AP180 regulates the generation of amyloid-beta peptide. Biochem Biophys Res Commun 385, 247-250.
17. Cheung JC, Salerno B, Hanakahi LA (2008) Evidence for an inositol hexakisphosphate-dependent role for Ku in mammalian nonhomologous end joining that is independent of its role in the DNA-dependent protein kinase. Nucleic Acids Res 36, 5713-5726.
18. Bolger TA, Folkmann AW, Tran EJ, Wente SR (2008) The mRNA export factor Gle1 and inositol hexakisphosphate regulate distinct stages of translation. Cell 134, 624-633.
19. Jariwalla RJ (1999) Inositol hexaphosphate (IP6) as an anti-neoplastic and lipid-lowering agent.Anticancer Res19, 3699-3702.
20. Pervaiz S, Holme AL, Aggarwal BB, Anekonda TS, Baur JA, Gojkovic-Bukarica L, Ragione FD, Kim AL, PirolaL,Saiko P (2009) Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 11, 2851-2897.
21. Mattson MP, Cheng A (2006) Neurohormetic phytochem-icals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci 29, 632-639.
22. Smith JJ, Kenney RD, Gagne DJ, Frushour BP, Ladd W, Galonek HL, Israelian K, Song J, Razvadauskaite G, Lynch AV, Carney DP, Johnson RJ, Lavu S, Iffland A, Elliott PJ, Lambert PD, Elliston KO, Jirousek MR, Milne JC, Boss O (2009) Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol 3, 31.
23. Murphy AM, Otto B, Brearley CA, Carr JP, Hanke DE (2008) A role for inositol hexakisphosphate in the maintenance of basal resistance to plant pathogens. Plant J 56, 638-652.
24. Anekonda TS (2006) Resveratrol-A boon for treating Alzheimer's disease? Brain Res Rev 52, 316-326.
25. Anekonda TS, Reddy PH (2005) Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res Brain Res Rev 50, 361-376.
26. Lavu S, Boss O, Elliott PJ, Lambert PD (2008) Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7, 841-853.
27. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N Jr., Bennett DA, Calon F (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68, 48-58.
28. Suchankova G, Nelson LE, Gerhart-Hines Z, Kelly M, Gauthier MS, Saha AK, Ido Y, Puigserver P, Ruderman NB (2009) Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. Biochem Biophys Res Commun 378, 836-841.
29. Weyrich P, Machicao F, Reinhardt J, Machann J, Schick F, Tschritter O, Stefan N, Fritsche A, Haring HU (2008) SIRT1 genetic variants associate with the metabolic response ofCau-casians to a controlled lifestyle intervention-the TULIP Study. BMC Med Genet 9, 100.
30. Ramsey KM, Mills KF, Satoh A, Imai S (2008) Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7, 78-88.
31. Kwon HS, Ott M (2008) The ups and downs of SIRT1. Trends Biochem Sci 33, 517-525.
32. Ghosh HS (2008) The anti-aging, metabolism potential of SIRT1. Curr Opin Investig Drugs 9, 1095-1102.
33. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26, 3169-3179.
34. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA, Pasinetti GM (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281, 21745-21754.
35. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, McDonagh T, Lemieux M, McBurney M, Szilvasi A, Easlon EJ, Lin SJ, GuarenteL(2006) Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 4, e31.
36. Guarente L, Picard F (2005) Calorie restriction-the SIR2 connection. Cell 120, 473-482.
37. Guarente L (2005) Calorie restriction and SIR2 genes-towards a mechanism. Mech Ageing Dev 126, 923-928. (Pubitemid 41033172)
38. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390-392.
39. Anekonda TS, Reddy PH (2006) Neuronal protection by sir-tuins in Alzheimer's disease. J Neurochem 96, 305-313.
40. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW, Finkel T (2008) A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA 105, 3374-3379.
41. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 118, 2190-2199.
42. Park JH, Park YS, Rhim SY, Jhee OH, Kim SH, Yang SC, Lee MH, Shaw LM, Kang JS (2009) Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study.J ChromatogrB Analyt Technol Biomed Life Sci 877, 59-64.
43. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA (2008) Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 326, 196-208.
44. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci 28, 6926-6937.
45. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of Abeta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
46. Quinn J, Kulhanek D, Nowlin J, Jones R, Pratico D, Rokach J, Stackman R (2005) Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res 1037, 209-213.
47. Caballero B, Vega-Naredo I, Sierra V, DeGonzalo-Calvo D, Medrano-Campillo P, Guerrero JM, Tolivia D, Rodriguez-Colunga MJ, Coto-Montes A (2009) Autophagy upregulation and loss of NF-kappaB in oxidative stress-related immunod-eficient SAMP8 mice. Mech Ageing Dev 130, 722-730.
48. Salminen A, Kaarniranta K (2009) SIRT1: regulation of longevity via autophagy. Cell Signal 21, 1356-1360.
49. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, GriffithD,GrifforM,LoulakisP,PabstB,Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285, 8340-8351.
50. Morrison BH, Tang Z, Jacobs BS, Bauer JA, Lindner DJ (2005)Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma. Biochem J 385, 595-603.
51. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 285, 9100-9113.
52. Dasgupta B, Milbrandt J (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104, 7217-7222.
53. Maezawa I, Hong HS, Wu HC, Battina SK, Rana S, Iwamoto T, Radke GA, Pettersson E, Martin GM, Hua DH, Jin LW (2006)A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. J Neurochem 98, 57-67.
54. Sebastia J, Pertusa M, Vilchez D, Planas AM, Verbeek R, Rodriguez-Farre E, Cristofol R, Sanfeliu C (2006) Carboxyl-terminal fragment of amyloid precursor protein and hydrogen peroxide induce neuronal cell death through different pathways. J Neural Transm 113, 1837-1845.
55. Sopher BL, Fukuchi K, Kavanagh TJ, Furlong CE, Martin GM (1996) Neurodegenerative mechanismsinAlzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death. Mol Chem Neuropathol 29, 153-168.
56. Sopher BL, Fukuchi K, Smith AC, Leppig KA, Furlong CE, Martin GM (1994) Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. Brain Res Mol Brain Res 26, 207-217.
57. Woltjer RL, McMahan W, Milatovic D, Kjerulf JD, Shie FS, Rung LG, Montine KS, Montine TJ (2007) Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxy-terminal fragment. Neurobiol Dis 25, 427-437.
58. Woltjer RL, Nghiem W, Maezawa I, Milatovic D, Vaisar T, Montine KS, Montine TJ (2005) Role of glutathione in intra-cellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. J Neu-rochem 93, 1047-1056.
59. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
60. Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF (2008) Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis 14, 225-234.
61. Woltjer RL, Cimino PJ, Boutte AM, Schantz AM, Montine KS, Larson EB, Bird T, Quinn JF, Zhang J, MontineTJ (2005) Proteomic determinationofwidespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. FASEB J 19, 1923-1925.
62. Anekonda TS, Adamus G (2008) Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70. BMC Res Notes 1, 122.
63. Choi HS, Kim JW, Cha YN, Kim C (2006) A quantitative nitroblue tetrazolium assay for determining intracellular superoxide anion productioninphagocytic cells. J Immunoas-say Immunochem 27, 31-44.
64. Schosinsky KH, Lehmann HP, Beeler MF (1974) Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 20, 1556-1563.
65. Quinn JF, Harris CJ, Cobbb KE, Domes C, Ralle M, Brewer G, Wadsworth TL (2010) A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 21, 903-914.
66. Parker MM, Humoller FL, Mahler DJ (1967) Determination of copper and zinc in biological material. Clin Chem 13, 40-48.
67. Cardoso SM, Pereira CF, Moreira PI, Arduino DM, Esteves AR, Oliveira CR (2009) Mitochondrial control of autophagic lysosomal pathway in Alzheimer's disease. Exp Neurol 223, 294-298.
68. Quinn J, Suh J, Moore MM, Kaye J, Frei B (2003) Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain. J Alzheimers Dis 5, 309-313.
69. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman RW Jr (2007) Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 28, 213-225.
70. Baur JA, Sinclair DA (2006) Therapeutic potential of resver-atrol: the in vivo evidence. Nat Rev Drug Discov 5, 493-506.
71. Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, Supprian T, Herrmann W, Obeid R, Multhaup G, Falkai P, Bayer TA (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplas-min in patients with Alzheimer's disease. J Neural Transm 113, 1763-1769.
72. Hong HS, Maezawa I, Yao N, Xu B, Diaz-Avalos R, Rana S, Hua DH, Cheng RH, Lam KS, Jin LW (2007) Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity. Brain Res 1130, 223-234.
73. Jin LW, Hua DH, Shie FS, Maezawa I, Sopher B, Martin GM (2002) Novel tricyclic pyrone compounds prevent intracellu-lar APP C99-induced cell death. J Mol Neurosci 19, 57-61.
74. Lin CL, Chen TF, Chiu MJ, Way TD, Lin JK (2009) Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation. Neurobiol Aging 30, 81-92.
75. United States Food and Drug Administration (1975) Select Committee on GRAS Substances, Calcium Phytate, 21 CFR Section 582.6219, p. 6219.
76. Verghese M, Rao DR, Chawan CB, Walker LT, Shackelford L (2006) Anticarcinogenic effect of phytic acid (IP6): apoptosis as a possible mechanism of action. LWT 39, 1093-1098.
77. GrafH (1986) Phytic Acid: Chemistry& Applications, Pilatus Press, Minneapolis, MN.
78. Raboy V (2003) myo-Inositol-1,2,3,4,5,6-hexakisphosphate. Phytochemistry 64, 1033-1043.
79. Bohn L, Meyer AS, Rasmussen SK (2008) Phytate: impact on environment and human nutrition. A challenge for molecular breeding. J Zhejiang Univ Sci B 9, 165-191.
80. Badone FC, Cassani E, Landoni M, Doria E, Panzeri D, Lago C, Mesiti F, Nielsen E, Pilu R (2010) The low phytic acid1-241 (lpa1-241) maize mutation alters the accumulation of anthocyanin pigment in the kernel. Planta 231, 1189-1199.
81. Emami K, Morris NJ, Cockell SJ, Golebiowska G, Shu QY, Gatehouse AM (2010) Changes in protein expression profiles between a low phytic acid rice (Oryza sativa L. ssp. japon-ica) line and its parental line: a proteomic and bioinformatic approach. J Agric Food Chem 58, 6912-6922.
82. Graf E, Empson KL, Eaton JW (1987) Phytic acid. A natural antioxidant. J Biol Chem 262, 11647-11650.
83. Vucenik I, Shamsuddin AM (2006) Protection against cancer by dietary IP6 and inositol. Nutr Cancer 55, 109-125.
84. Jariwalla RJ, Sabin R, Lawson S, Bloch DA, Prender M, Andrews V, Herman ZS (1988) Effect of dietary phytic acid (phytate) on the incidence and growth rate of tumors promoted in Fisher rats by magnesium supplement. Nutr Res 8, 813-827.
85. Qin W, Zhao W, Ho L, Wang J, Walsh K, Gandy S, Pasinetti GM (2008) Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. Ann N Y Acad Sci 1147, 335-347.
86. Grases F, Simonet BM, Prieto RM, March JG (2001) Phytate levels in diverse rat tissues: influence of dietary phytate. Br J Nutr 86, 225-231.
87. Fenili D, Brown M, Rappaport R, McLaurin J (2007) Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med 85, 603-611.
88. Sun Y, Zhang G, Hawkes CA, Shaw JE, McLaurin J, Nitz M (2008) Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation. Bioorg Med Chem 16, 7177-7184.
89. Vasdev N, Chio J, van Oosten EM, Nitz M, McLaurin J, Vines DC, Houle S, Reilly RM, Wilson AA (2009) Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scyllo-inositol. Chem Commun (Camb) 37, 5527-5529.
90. Henneman PH, Benedict PH, Forbes AP, Dudley HR (1958) Idiopathic hypercaicuria. New Engl J Med 259, 802-807.
91. Grases F, Simonet BM, Vucenik I, Prieto RM, Costa-Bauza A, March JG, Shamsuddin AM (2001) Absorption and excretion of orally administered inositol hexaphos-phate (IP(6) or phytate) in humans. Biofactors 15, 53-61.